Brief: Blis Technologies receives Streptococcus Salivarius Blis K12 approval
21/11/2017 02:54
Nov 21 (Reuters) - Blis Technologies Ltd BLT.NZ :
* Australian Therapeutic Goods Administration approved
Streptococcus Salivarius Blis K12
* Streptococcus Salivarius Blis K12 approved as active
ingredient
for listed complementary medicines
Source text for Eikon: urn:newsml:reuters.com:*:nNZW2nH4LJ
Further company coverage: BLT.NZ
(bangalore.newsroom@thomsonreuters.com)
Recent news on BLIS Technologies
See all newsBrief: Blis Technologies Says Strong 1Q27 Supports Growth Outlook
New Zealand's BLIS Technologies Q1 revenue rises on ingredient sales growth
Brief: BLIS Technologies Posts Q1 EBITDA Of NZD 1.1 million
New Zealand's BLIS Technologies advances on upbeat annual results
Brief: BLIS Technologies Says Co Suffered Minimal Economic Loss From Uncertainty Surrounding Middle East